No Data
B. Riley Securities Reiterates Buy on Harrow, Raises Price Target to $29
B. Riley Securities analyst Sahil Kazmi reiterates Harrow with a Buy and raises the price target from $26 to $29.
Harrow Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 69.59% B. Riley Securities $26 → $29 Reiterates Buy → Buy 04/11/2024 40.35% Craig-Hallum → $24
Harrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor
Harrow Inc (HROW) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic Advances
Earnings Call Summary | Harrow(HROW.US) Q1 2024 Earnings Conference
The following is a summary of the Harrow, Inc. (HROW) Q1 2024 Earnings Call Transcript:Financial Performance:Harrow Inc. reported a rise of 33% in revenues for Q1 2024 compared to Q1 2023.Increased it
Harrow Health's Promising Growth Trajectory and Strong Financial Outlook Reinforce Buy Rating